Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Topiramate ER Prior Auth | Open…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Topiramate ER Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity limits for Trokendi XR and Qudexy XR extended-release topiramate capsules for Boeing commercial members. Coverage requires qualifying clinical criteria, absence of FDA-labeled contraindications, and compliance with the applicable 30-day quantity limit unless an approved exception applies.

    Policy Summary
    PayerPrime Therapeutics
    PolicyTopiramate ER Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 15, 2026
    Next Review DateN/A
    Key ActionDocument the qualifying diagnosis or indication, relevant age or clinical support, medication history when applicable, and absence of FDA-labeled contraindications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    30 daysQuantity-limit supply
    30 or 60Quantity limits
    5Qudexy XR strengths

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4Trokendi XR strengths
    AHFS/DrugDex 1, 2a, 2bCompendia evidence

    Coverage Criteria

    Initial Therapy Criteria

    Target agent(s) will be approved when BOTH of the following are met.

    Initial therapy

    • Qualifying pathway

      • Medication-history pathway: The patient has a medication history of use of an anti-seizure medication that is not topiramate.
      • Indication pathway

        • Qualifying diagnosis or indication: Partial onset seizures; primary generalized tonic-clonic seizures; Lennox-Gastaut Syndrome; migraine; or another FDA-labeled indication for the requested agent and route of administration.
        • Age or evidence support when an FDA-labeled indication is used: The patient's age is within FDA labeling for the requested indication; there is support for use of the requested agent for the patient's age and indication; or the indication is supported in compendia for the requested agent and route of administration.AHFS or DrugDex level 1, 2a, or 2b
    • Contraindication requirement: The patient does not have any FDA-labeled contraindications to the requested agent.

    Continuation or Renewal Therapy

    Target agent(s) will be approved when ALL of the following are met.

    Renewal therapy

    • Prior plan approval: The patient has been previously approved for the requested agent through the plan's Prior Authorization process.
    • Benefit or medication history: The patient has had clinical benefit with the requested agent, or has a medication history of use of an anti-seizure medication that is not topiramate.
    • Contraindication requirement: The patient does not have any FDA-labeled contraindications to the requested agent.

    Quantity-Limit Exception

    A quantity-limit exception may be approved when the requested quantity exceeds the program limit and one of the following exception pathways is met.

    Quantity-limit criteria

    • Within program limit: The requested quantity or dose does not exceed the program quantity limit.
    • Higher dose without maximum FDA-labeled dose: The requested agent does not have a maximum FDA-labeled dose for the requested indication, and there is support for therapy with a higher dose for the requested indication.
    • Lower quantity of higher strength cannot achieve dose: The requested quantity does not exceed the maximum FDA-labeled dose for the requested indication, and there is support for why the requested quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
    • Higher-than-labeled dose support:

    Patients with an FDA-labeled contraindication to the requested agent are excluded from approval.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required

    For initial authorization, document that the patient has either a medication history of an anti-seizure medication other than topiramate or a qualifying indication pathway. The patient must also have no FDA-labeled contraindication to the requested agent.

    • Qualifying indications include partial onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, migraine, or another FDA-labeled indication for the requested agent and route of administration.
    • For an FDA-labeled indication, document that the patient is within the FDA-labeled age range, that there is support for use at the patient's age, or that the indication is supported in AHFS or DrugDex at level 1, 2a, or 2b.
    • Approval duration: 12 months. If a quantity limit applies, submit under the Quantity Limit Criteria.
    Prior Authorization

    Renewal Authorization Required

    For renewal authorization, document that the patient was previously approved for the requested agent through the plan's Prior Authorization process and that the patient has clinical benefit with the agent or a medication history of an anti-seizure medication other than topiramate. The patient must also have no FDA-labeled contraindication to the requested agent.

    Therapy Background

    Topiramate extended-release capsules are anti-seizure therapies used for conditions including partial onset seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut Syndrome. The policy also recognizes migraine and other FDA-labeled indications for the requested agent and route of administration. Initial and renewal approvals are issued for 12 months when the applicable clinical criteria are met.

    Definitions and Supporting Evidence

    Compendia allowed
    Accepted compendiaAHFS or DrugDex
    Evidence levels1, 2a, or 2b
    UseSupport for the requested agent and route of administration
    Anti-seizure medication history
    Medication typeAnti-seizure medication
    Topiramate statusThe medication must not be topiramate
    DocumentationUse documented medication history showing prior use

    Initial Therapy

    Initial Therapy Criteria

    Initial approval requires BOTH a qualifying clinical pathway and no FDA-labeled contraindication.

    Initial requirements

    • Qualifying clinical pathway

      • Medication-history pathway: The patient has a medication history of use of an anti-seizure medication that is not topiramate.
      • Qualifying indication pathway: The patient has partial onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut Syndrome, migraine, or another FDA-labeled indication for the requested agent and route of administration, with the applicable age or clinical support.
    • No contraindication: The patient does not have any FDA-labeled contraindications to the requested agent.

    Renewal Therapy

    Continuation Criteria

    Renewal approval requires ALL of the following.

    Renewal requirements

    • Previous approval: The patient has been previously approved for the requested agent through the plan's Prior Authorization process.
    • Clinical benefit or medication history: The patient has had clinical benefit with the requested agent, or has a medication history of use of an anti-seizure medication that is not topiramate.
    • No contraindication: The patient does not have any FDA-labeled contraindications to the requested agent.

    Program Quantity Limits

    Qudexy XR 100 mg quantity limit
    Product and strengthQudexy XR 100 mg
    Quantity limit30 capsules
    Supply period30-day supply
    Qudexy XR 150 mg quantity limit
    Product and strengthQudexy XR 150 mg
    Quantity limit30 capsules
    Supply period30-day supply
    Policy Summary
    PayerPrime Therapeutics
    PolicyTopiramate ER Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 15, 2026
    Next Review DateN/A
    Key ActionDocument the qualifying diagnosis or indication, relevant age or clinical support, medication history when applicable, and absence of FDA-labeled contraindications.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsTherapy BackgroundDefinitions and Supporting EvidenceInitial TherapyRenewal TherapyProgram Quantity Limits
    The requested quantity exceeds the maximum FDA-labeled dose for the requested indication, and there is support for therapy with a higher dose for the requested indication.
    • Patients without prior plan approval require initial evaluation review.
    • Approval duration: 12 months. If a quantity limit applies, submit under the Quantity Limit Criteria.
    Documentation Required

    Clinical Documentation: Initial or Renewal

    For initial or renewal review, submit clinical documentation supporting the applicable medication history or indication pathway and confirming the requested agent and route of administration. Documentation must support age appropriateness or accepted compendia support when relying on an FDA-labeled indication.

    • Initial medication-history pathway: use of an anti-seizure medication that is not topiramate.
    • Initial indication pathway: partial onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, migraine, or another FDA-labeled indication for the requested agent and route.
    • For an FDA-labeled indication, document age within labeling, support for use at the patient's age, or AHFS/DrugDex support at evidence level 1, 2a, or 2b.
    • Document absence of FDA-labeled contraindications to the requested agent.
    Documentation Required

    Renewal Documentation Required

    For renewal, submit the prior authorization history showing that the requested agent was previously approved through the plan and provide documentation of clinical benefit or the qualifying medication-history pathway. Also document that no FDA-labeled contraindication is present.

    • Clinical-benefit documentation must support continued benefit with the requested agent.
    • Alternatively, document a medication history of an anti-seizure medication other than topiramate.
    • Patients without prior plan approval require initial evaluation review.
    Documentation Required

    Quantity-Limit Exception Documentation

    When the requested quantity exceeds the program quantity limit, submit documentation supporting the higher-dose exception and the applicable FDA-labeled dose rationale.

    • If there is no maximum FDA-labeled dose for the indication, document support for therapy with a higher dose.
    • If the quantity does not exceed the maximum FDA-labeled dose, document why the requested quantity cannot be achieved with a lower quantity of a higher strength that remains within the program quantity limit.
    • If the requested quantity exceeds the maximum FDA-labeled dose, document support for therapy with the higher dose.
    • Approval duration for a quantity-limit exception: 12 months.
    Denial Risk

    Clinical Criteria or Contraindication Failure

    Authorization may be denied when the applicable initial or renewal clinical criteria are not met or when the requested agent has an FDA-labeled contraindication for the patient.

    • Initial review fails if neither the qualifying anti-seizure medication history nor the required indication pathway is documented.
    • Renewal review fails if prior plan approval and either clinical benefit or the qualifying medication history are not documented.
    • FDA-labeled contraindications must be absent for both initial and renewal approval.
    Denial Risk

    Unsupported Quantity-Limit Override

    A quantity-limit override may be denied when the requested quantity exceeds the program limit and the applicable higher-dose, FDA-labeled-dose, or exception-support requirements are not documented.

    • For an indication without a maximum FDA-labeled dose, support for higher-dose therapy is required.
    • For a quantity within the maximum FDA-labeled dose, support is required explaining why a lower quantity of a higher strength within the program limit cannot be used.
    • For a quantity above the maximum FDA-labeled dose, support for therapy with the higher dose is required.
    Qudexy XR 200 mg quantity limit
    Product and strengthQudexy XR 200 mg
    Quantity limit60 capsules
    Supply period30-day supply
    Qudexy XR 25 mg quantity limit
    Product and strengthQudexy XR 25 mg
    Quantity limit30 capsules
    Supply period30-day supply
    Qudexy XR 50 mg quantity limit
    Product and strengthQudexy XR 50 mg
    Quantity limit30 capsules
    Supply period30-day supply
    Trokendi XR 100 mg quantity limit
    Product and strengthTrokendi XR 100 mg
    Quantity limit30 capsules
    Supply period30-day supply
    Trokendi XR 200 mg quantity limit
    Product and strengthTrokendi XR 200 mg
    Quantity limit60 capsules
    Supply period30-day supply
    Trokendi XR 25 mg quantity limit
    Product and strengthTrokendi XR 25 mg
    Quantity limit30 capsules
    Supply period30-day supply
    Trokendi XR 50 mg quantity limit
    Product and strengthTrokendi XR 50 mg
    Quantity limit30 capsules
    Supply period30-day supply